News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
Tuesday, November 19, 2024Curium a world leader in nuclear medicine announced that it has completed enrollment of its Phase SOLARRECUR clinical trial The trial is a multicenter openlabel study to evaluate the diagnostic performance of copper Cu PSMA IT PETCT in men with su...
LIfT BioSciences expands into Ireland for manufacturing & clinical operations
Monday, November 18, 2024LIfT BioSciences a rapidly emerging biotech company preparing to start clinical trials for its firstinclass allogeneic innate cell therapy today announces the expansion of its manufacturing and clinical operations with the opening of a new subsidiary...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Saturday, November 16, 2024Sandoz the global leader in generic and biosimilar medicines today announced that the European Commission EC has granted marketing authorization for Afqlir aflibercept mg vial kit and prefilled syringe for intravitreal injection a biosimilar to refe...
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
Friday, November 15, 2024Akari Therapeutics Plc announces the completion of the merger the Merger of Akari Therapeutics Plc the Company and Peak Bio Inc Peak Bio creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapie...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
Friday, November 15, 2024PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of LaNeo MDMA and novel derivatives of MDMA MDXX class molecules has signed a Letter of Intent with a research institution to provide its LaNe...
Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies
Thursday, November 14, 2024Continuity Biosciences LLC a new bioscience company dedicated to developing and commercializing cuttingedge technologies for cell reprogramming immune modulation and drug delivery is excited to announce its official launch The company seeks to bridge...
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
Thursday, November 14, 2024WuXi Biologicsa leading global Contract Research Development and Manufacturing Organization CRDMO announced that it will enhance its drug product DP capabilities at the companys facility in Leverkusen Germany with a new sterile filling line for prefi...
QIAGEN collaborates with McGill University to advance microbiome research
Wednesday, November 13, 2024QIAGEN announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes The threeyear partnership will further drive microbiome sciences the study of a community of microorgan...
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
Wednesday, November 13, 2024Nxera Pharma Co Ltd formerly known as Sosei Group or Sosei Heptares notes that Centessa Pharmaceuticals has initiated a Phase trial of ORX an investigational orally administered highly potent and selective orexin receptor
ResQ Pharma Receives PDUFA Date for LipidRescue™ as a Potential First-Ever, FDA-approved Treatment for LAST
Tuesday, November 12, 2024ResQ Pharma Inc a Chicagobased pharmaceutical company developing and commercializing innovative drug therapies today announced that it has received a PDUFA Prescription Drug User Fee Act date of June for its LipidRescue Kit If approved
